Igor Puzanov
Faculty Member
Last active: 3/10/2014

Igor Puzanov, M.D.

Official Affiliation: Medicine

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

  1. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS (2013) J Immunother 36(9): 490-5
    › Primary publication · 24145360 (PubMed)
  2. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M (2013) J Transl Med : 137
    › Primary publication · 23731854 (PubMed) · PMC3681569 (PubMed Central)
  3. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A (2013) J Clin Oncol 31(14): 1767-74
    › Primary publication · 23569304 (PubMed)
  4. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA (2013) Clin Cancer Res 19(3): 721-30
    › Primary publication · 23251007 (PubMed) · PMC6485439 (PubMed Central)
  5. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T, Czech Renal Cancer Cooperative Group (2012) Ann Oncol 23(12): 3137-3143
    › Primary publication · 22700990 (PubMed)
  6. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ (2012) Cancer 118(24): 6055-62
    › Primary publication · 22674198 (PubMed) · PMC3934426 (PubMed Central)
  7. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Patrawala S, Puzanov I (2012) Future Oncol 8(5): 509-23
    › Primary publication · 22646766 (PubMed)
  8. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F (2012) Oncologist 17(12): 1534-40
    › Primary publication · 22622146 (PubMed) · PMC3528385 (PubMed Central)
  9. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J (2012) Clin Cancer Res 18(12): 3414-27
    › Primary publication · 22510349 (PubMed)
  10. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Lancet Oncol 13(5): 459-65
    › Primary publication · 22456429 (PubMed)

Featured Affiliation

View all affiliations

Contact Information

2220 Pierce Avenue
777 PRB
Nashville, TN 37232
USA
615-322-4967 (p)
615-323-7602 (f)
Email

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword

Apoptosis Carcinoma, Squamous Cell Cell Differentiation Cell Lineage Cetuximab Chemokines Clinical Trials, Phase I as Topic Drug Resistance Edema Extracellular Signal-Regulated MAP Kinases Follow-Up Studies Gene Expression Regulation, Neoplastic Hematopoietic Stem Cells Histocompatibility Antigens Class I Histones Humans Ipilimumab Kaplan-Meier Estimate Lymphocytes MAP Kinase Signaling System Mutation NF-kappa B Ovarian Neoplasms Point Mutation Pyridines Rats Skin Sorafenib Substrate Specificity Tartrate-Resistant Acid Phosphatase